

Virginia Medicaid
Pharmacy & Therapeutics Committee Meeting
Agenda
600 East Broad Street – 7th Floor Conference Rooms
Richmond, VA 23219
Thursday, March 21, 2019 – 10 AM

Welcome and Comments

Jennifer Lee, MD, Agency Director

Call to Order

Chethan Bachireddy, MD, Acting CMO, Chair

Drug Utilization Review (DUR) Board Report

Kathy Sardegna, MD

Approval of Minutes from September 26, 2018 Meeting

P&T Committee Members

PDL Management

P&T Committee Members

- **Potential New Therapeutic Class Review (PDL Category)**

- Calcitonin Gene-Related Peptide CGRP (Antimigraine Preparations)

- **PDL Phase I – New Drug Review (Therapeutic Class)**

- Brand Drugs**

- Arikayce™ (Antibiotics, Inhaled)
 - Epidiolex®, Sympazan™ (Anticonvulsants)
 - Abilify® Mycite, Perseris™ (Antipsychotics)
 - Bryhali™, Impoyz™, Nolix® (Steroids)
 - Inveltys™, Dexycu™ (Ophthalmic -Anti-inflammatory Agents)
 - Xelpros™ (Ophthalmic - Prostaglandin Analogs)
 - Yupelri™ (COPD)

- Generics Drugs or New Dosage Forms**

- Ledipasvir, Sofosbuvir (Hepatitis C Agents)
 - fenofibrate (generics Triglide®) (Lipotropics other)
 - clobazam (generic Onfi® susp/tab) (Anticonvulsants)
 - bupropion XL (generic Forfivo® XL) (Antidepressants)
 - hydrocortisone butyrate (generic Locoid® lotion) desoximetasone (generic Topicort® spray) (Steroids)

- **PDL Phase II – Annual Review: Therapeutic Classes with Updates**

- Analgesics**

- Opioid Dependency (includes oral buprenorphine (Closed Class) & methadone)
 - Opioids: Short Acting (includes combination drugs and lozenges)

- Antibiotics / Anti-Infectives**

- Antibiotics (topical)
 - Antifungals (oral)
 - Cephalosporins (Second and Third Generations)
 - Gastrointestinal, Antibiotics
 - Quinolones (Second and Third Generations)

- Antivirals**

- Antivirals for Herpes (HSV)
 - Antivirals for Influenza

- Blood Modifiers**

- Antihyperuricemics

- Erythropoiesis Stimulating Proteins

Cardiac

- Anticoagulants (*includes oral agents, low molecular weight heparins & Factor XA Inhibitors*) (Closed Class)
- Platelet Aggregation Inhibitors

Central Nervous System

- Antihyperkinesia/CNS Stimulants (Closed Class)
- Multiple Sclerosis Agents
- Neuropathic Pain

Contraceptives

- Long-Acting Reversible Contraceptives (includes IUDs & injectables)

Dermatologic Agents (Topical)

- Acne Agents (*includes benzoyl peroxide, clindamycin, retinoids & combinations*)
- Antivirals, topical
- Psoriasis Agents

Endocrine and Metabolic Agents

- Androgenic Agents
- Bone Resorption Suppression and Related Agents (*includes bisphosphonates, calcitonins and others*)
- Hypoglycemics: Incretin Mimetics/Enhancers (*includes DPP-IV Inhibitors, GLP-1 Agonists & comb*) (Closed Class)
- Hypoglycemics: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor (Closed Class)

Immunological Agents

- Self-administered Cytokine & CAM Antagonists with Related Agents including Methotrexate (*all indications: Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Ankylosing Spondylitis (AS), Plaque Psoriasis, Psoriatic Arthritis (PsA), Crohn's Disease (CD), Ulcerative Colitis, Cryopyrin-Associated Periodic Syndromes (CAPS)*) (Closed class)

PDL Phase II – Annual Review: Therapeutic Classes without Significant Updates (reviewed by the Department)

Analgesics

- Antimigraine
- Non-Steroidal Anti-Inflammatory Drugs (NSAID) (includes Cox-2 inhibitors and topical agents)
- Opioids: Long Acting

Antibiotics / Anti-Infectives

- Ketolides & Macrolides (Adult and Pediatric)
- Quinolones (Otic)

Dermatologic Agents (Topical)

- Antifungal Agents
- Rosacea Agents

Neuropathic Pain

- Non-Ergot Dopamine Receptor Agonists
- Skeletal Muscle Relaxants
- Smoking Cessation Agents

Endocrine and Metabolic Agents

- Estrogens (vaginal and oral)
- Hypoglycemics: Alpha-Glucosidase Inhibitors

- Hypoglycemics: Insulins
- Hypoglycemics: Meglitinides
- Hypoglycemics: Metformins
- Hypoglycemics: Sulfonylureas
- Hypoglycemics: Thiazolidinediones
- Pancreatic Enzymes
- Progestational Agent

Confidential Meeting (Pricing Information Discussion)

P&T Committee Members & DMAS Staff

***Criteria Discussion of Potential New Therapeutic Class**

P&T Committee Members

Criteria Discussion of Phase I New Drugs

P&T Committee Members

Criteria Discussion of Phase II Drugs

P&T Committee Members

**Criteria discussions will be held for classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions.*

Next Meeting – September 19, 2019 (tentative)

Chair

Oral Presentations: The P&T Committee in conjunction with the Department will be allocating time slots for interested parties to present scientific and clinical information on **only** the drug classes in Phase II which are scheduled for review at the March meeting and new drugs in PDL Phase I listed on the Agenda. **All presentations must include information published in a peer reviewed journal (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:**

- PDL Phase II Annual Reviews – March 2018 to present
- New Drugs in PDL Phase I or II Drug Classes – March 2017 to present

No anecdotal accounts are to be given. Each speaker will be allocated no more than 2 minutes to present. Speakers will be decided by the Chairperson based on relevancy of the information. **Speakers must receive a confirmation number to verify the presentation is scheduled.**

Anyone interested in providing specific clinical information to the Committee at the meeting must submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter. Please send requested information to pdlinput@dmass.virginia.gov and dfmoody@magellanhealth.com by **5 p.m. EST on Monday, February 18, 2019.**

Written information/comments: The P&T Committee will also accept written comments for consideration. Please send statements to pdlinput@dmass.virginia.gov by **5 p.m. EST Monday, February 18, 2019.**